DICE News and Press, DICE Therapeutics Inc. From 06/20/23

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology PR Newswire INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif. , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a...

SOUTH SAN FRANCISCO, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in im...

2023-05-24 13:50:08 ET Wells Fargo has initiated DICE Therapeutics ( NASDAQ: DICE ) at equalweight saying that the company doesn't have any near-term catalysts and upcoming competitor datasets may weigh on shares. The firm has a $38 price target (~11% upside based on Tuesday's c...

2023-05-11 18:13:57 ET DICE Therapeutics press release ( NASDAQ: DICE ): Q1 GAAP EPS of -$0.54. Cash Position: Cash, cash equivalents and marketable securities totaled $554.5 million at March 31, 2023. R&D Expenses: Research and development expenses were $23.7 mill...

First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasis Topline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy volunteers expected in 2H 2023 Strong financial position with $554.5 mi...

2023-05-08 05:28:36 ET Summary Shares of oral monoclonal antibody developer DICE Therapeutics, Inc. (DICE) go into the spotlight for the first time today. The company recently posted encouraging Phase 1c data from its lead candidate, psoriasis therapy DC-806, which demonstrated bo...

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in imm...

2023-04-05 13:10:09 ET Summary The month of March had a couple of very interesting insider purchases. In this article, we discuss some of the biggest insider purchases by value. In addition, we will take a look into 2 companies more in-depth, which we found particularly intere...

SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in i...

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...